TABLE 1.
Clinical performance of ePlex BCID-FP panel with comparator methodse
| Species | Sensitivity/PPA |
Specificity/NPA |
||
|---|---|---|---|---|
| TP/TP + FN | % (95% CI) | TN/TN + FP | % (95% CI) | |
| Candida albicans | ||||
| Clinical | 53/54 | 98.1 (90.2–99.7) | 87/87 | 100 (95.8–100) |
| Contrived | 13/14 | 92.9 (68.5–98.7) | 710/711 | 99.9 (99.2–100) |
| Combined | 66/68 | 97.1 (89.9–99.2) | 797/798 | 99.9 (99.3–100) |
| Candida auris | ||||
| Clinical | 0/0 | 141/141 | 100 (97.3–100) | |
| Contrived | 49/49 | 100 (92.7–100) | 676/676 | 100 (99.4–100) |
| Combined | 49/49 | 100 (92.7–100) | 817/817 | 100 (99.5–100) |
| Candida dubliniensis | ||||
| Clinical | 4/4 | 100 (51.0–100) | 137/137 | 100 (97.3–100) |
| Contrived | 48/48 | 100 (92.6–100) | 677/677 | 100 (99.4–100) |
| Combined | 52/52 | 100 (93.1–100) | 814/814 | 100 (99.5–100) |
| Candida famata | ||||
| Clinical | 0/0 | 141/141 | 100 (97.3–100) | |
| Contrived | 51/51 | 100 (93.0–100) | 674/674 | 100 (99.4–100) |
| Combined | 51/51 | 100 (93.0–100) | 815/815 | 100 (99.5–100) |
| Candida glabrata | ||||
| Clinical | 43/44 (45/46a) | 97.7 (88.2–99.6) | 95/97a (95/95a ) | 97.9 (92.8–99.4) |
| Contrived | 16/16 | 100 (80.6–100) | 709/709 | 100 (99.5–100) |
| Combined | 59/60 | 98.3 (91.1–99.7) | 804/806 | 99.8 (99.1–99.9) |
| Candida guilliermondii | ||||
| Clinical | 0/0 | 141/141 | 100 (97.3–100) | |
| Contrived | 49/50 | 98.0 (89.5–99.6) | 675/675 | 100 (99.4–100) |
| Combined | 49/50 | 98.0 (89.5–99.6) | 816/816 | 100 (99.5–100) |
| Candida kefyr | ||||
| Clinical | 0/0 | 141/141 | 100 (97.3–100) | |
| Contrived | 51/51 | 100 (93.0–100) | 672/674 | 99.7 (98.9–99.9) |
| Combined | 51/51 | 100 (93.0–100) | 813/815 | 99.8 (99.1–99.9) |
| Candida krusei | ||||
| Clinical | 4/4 | 100 (51.0–100) | 137/137 | 100 (97.3–100) |
| Contrived | 46/46 | 100 (92.3–100) | 679/679 | 100 (99.4–100) |
| Combined | 50/50 | 100 (92.9–100) | 816/816 | 100 (99.5–100) |
| Candida lusitaniae | ||||
| Clinical | 3/4 | 75.0 (30.1–95.4) | 137/137 | 100 (97.3–100) |
| Contrived | 45/45 | 100 (92.1–100) | 679/680 | 99.9 (99.2–100) |
| Combined | 48/49 | 98.0 (89.3–99.6) | 816/817 | 99.9 (99.3–100) |
| Candida parapsilosis | ||||
| Clinical | 18/19b (19/20c ) | 94.7 (75.4–99.1) | 121/122c (121/121c) | 99.2 (95.5–99.9) |
| Contrived | 41/41 | 100 (91.4–100) | 684/684 | 100 (99.4–100) |
| Combined | 59/60 | 98.3 (91.1–99.7) | 805/806 | 99.9 (99.3–100) |
| Candida tropicalis | ||||
| Clinical | 5/5 (6/6d ) | 100 (56.6–100) | 135/136 (135/135d ) | 99.3 (96.0–99.9) |
| Contrived | 45/45 | 100 (92.1–100) | 680/680 | 100 (99.4–100) |
| Combined | 50/50 | 100 (92.9–100) | 815/816 | 99.9 (99.3–100) |
| Cryptococcus gattii | ||||
| Clinical | 0/0 | 141/141 | 100 (97.3–100) | |
| Contrived | 50/50 | 100 (92.9–100) | 675/675 | 100 (99.4–100) |
| Combined | 50/50 | 100 (92.9–100) | 816/816 | 100 (99.5–100) |
| Cryptococcus neoformans | ||||
| Clinical | 5/5 | 100 (56.6–100) | 136/136 | 100 (97.3–100) |
| Contrived | 52/52 | 100 (93.1–100) | 673/673 | 100 (99.4–100) |
| Combined | 57/57 | 100 (93.7–100) | 809/809 | 100 (99.5–100) |
| Fusarium spp. | ||||
| Clinical | 0/0 | 141/141 | 100 (97.3–100) | |
| Contrived | 69/70 | 98.6 (92.3–99.7) | 655/655 | 100 (99.4–100) |
| Combined | 69/70 | 98.6 (92.3–99.7) | 796/796 | 100 (99.5–100) |
| Rhodotorula spp. | ||||
| Clinical | 2/2 | 100 (34.2–100) | 139/139 | 100 (97.3–100) |
| Contrived | 48/50 | 96.0 (86.5–98.9) | 674/675 | 99.9 (99.2–100) |
| Combined | 50/52 | 96.2 (87.0–98.9) | 813/814 | 99.9 (99.3–100) |
C. glabrata was detected by the ePlex BCID-FP panel in two samples that only grew C. lusitaniae (which was also detected by the ePlex BCID-FP Panel). C. glabrata was further detected in the residual of these two samples by PCR/sequencing, thus confirming these two samples were true positive for C. glabrata. These two samples are also listed as Case 6 and 7 in Table 3.
The false-negative sample is also listed as Case 3 in Table 3.
C. parapsilosis was detected by the ePlex BCID-FP panel in a sample that only grew C. dubliniensis (which was also detected by the ePlex BCID-FP panel). C. parapsilosis was further detected in the residual of that sample by PCR/sequencing, thus confirming this sample was true positive for C. parapsilosis. This sample is also listed as Case 4 in Table 3.
C. tropicalis was detected by the ePlex BCID-FP panel in a sample that only grew C. dubliniensis (which was also detected by the ePlex BCID-FP panel). C. tropicalis was further detected in the residual of that sample by PCR/sequencing, thus confirming this sample was true positive for C. tropicalis. This sample is also listed as Case 5 in Table 3.
PPA, positive percent agreement; NPA, negative percent agreement; TP, true positive; FN, false negative; TN, true negative; FP, false positive; CI, confidence interval.